1. Chimeric Antigen Receptor-T (CAR-T) Cells as "Living Drugs": A Clinical Pharmacist Perspective.
- Author
-
Murnane, Ciara, Gardiner, Nicola, Crehan, Olga, Bacon, Christopher L., McHugh, Ruth, Gilmer, John F., Mantalaris, Athanasios, and Panoskaltsis, Nicki
- Subjects
THERAPEUTIC use of antineoplastic agents ,THERAPEUTICS ,DRUG approval ,DRUG efficacy ,ATTITUDE (Psychology) ,CELL receptors ,PHARMACISTS' attitudes ,DRUG design ,BIOSIMILARS ,TREATMENT effectiveness ,HEALTH care teams ,HEMATOLOGIC malignancies ,T cells ,TUMORS ,IMMUNOTHERAPY ,PATIENT safety - Abstract
Background. Chimeric antigen receptor (CAR) T cell therapy, a "living drug" immunotherapy, harnesses the power of T-cells from a patient (autologous) or healthy donor (allogeneic) to target and kill cancer cells and has shown unprecedented outcomes in patients with relapsed and refractory malignancies. Treatment with CAR-T cells requires the application of unique skillsets in recognised specialist centres for successful outcomes and requires management by the multidisciplinary team incorporating the specialist pharmacist. Method. A multimodal research strategy was employed for this literature review whereby PubMed, Google Scholar, Embase, Stella Library Search, EMA website, and EBMT website were sources of information. The search was limited from 2020 onwards with key terms referring to CAR-T cell therapy. Results and Discussion. There are six CAR-T cell products currently approved by the European Medicines Agency (EMA) and Food and Drug Administration (FDA) which target haematological malignancies with abundant clinical trials underway exploring new and improved CAR designs and antigen targets. As CAR-T cell therapy is an advanced therapy medicinal product (ATMP), there is need for an extensive regulatory framework underpinning its safety and efficacy. The clinical pharmacist plays an integral role in the provision of safe and effective CAR-T cell therapy including governance, operational and clinical aspects of treatment. Pharmacists may also be involved through provision of "Qualified Person" (QP) expertise in clinical trials and for release within hospitals under certain circumstances. There is a need for harmonised and accessible guidance on the clinical delivery of ATMPs such as CAR-T cells, with fully delineated responsibilities of pharmacists involving the oversight and supervision of CAR-T cell treatment. Conclusion. There is an unmet need to provide suitable and applicable literature for clinical pharmacists who are involved in the delivery of CAR-T cells. We have provided an overview of T-cell biology and an explanation of CAR-T cell design and the biomanufacturing process. We reviewed the complex and multifaceted treatment cycle requiring considerable logistics, and described the involvement of the clinical pharmacist in each part of this cycle from patient selection to postinfusion care. Finally, we look to the challenges and future opportunities that will require the involvement of the clinical pharmacist. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF